Lack of generalizable evidence of the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis: comment on the article by Ringe et al.
Barthel
H Richard
HR
Vieth
Reinhold
R
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D002762:Cholecalciferol / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D005938:Glucocorticoids; D006887:Hydroxycholecalciferols; D002762:Cholecalciferol; C008088:alfacalcidol